RU2016129536A - Препараты на основе терпенов и каннабиноидов - Google Patents

Препараты на основе терпенов и каннабиноидов Download PDF

Info

Publication number
RU2016129536A
RU2016129536A RU2016129536A RU2016129536A RU2016129536A RU 2016129536 A RU2016129536 A RU 2016129536A RU 2016129536 A RU2016129536 A RU 2016129536A RU 2016129536 A RU2016129536 A RU 2016129536A RU 2016129536 A RU2016129536 A RU 2016129536A
Authority
RU
Russia
Prior art keywords
terpene
pinene
group
myrcene
terpenes
Prior art date
Application number
RU2016129536A
Other languages
English (en)
Inventor
Марк ДОНСКИ
Роберт ВИННИЦКИ
Original Assignee
Фулл Спектрум Лабораториз, Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Фулл Спектрум Лабораториз, Лтд. filed Critical Фулл Спектрум Лабораториз, Лтд.
Publication of RU2016129536A publication Critical patent/RU2016129536A/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
    • A23L2/52—Adding ingredients
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A61K31/015—Hydrocarbons carbocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/164—Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5015—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Dispersion Chemistry (AREA)
  • Mycology (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Polymers & Plastics (AREA)
  • Inorganic Chemistry (AREA)
  • Botany (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Claims (27)

1. Препарат с водной липосомной формулой терпена включающей:
первичный терпен, отобранный из группы, включающей α-пинен, α-бизаболол, β-пипен, гуаен, гуайол, лимонен, мирцен и оцимен;
вторичный терпен;
третичный терпен,
где первичный терпен в формуле составляет 50% (процент от массы), вторичный терпен - примерно от 30% до 40% (процент от массы) и третичный терпен - примерно от 8% до 10% (процент от массы).
2. Препарат по п. 1, отличающийся тем, что в формулу дополнительно включены один или несколько каннабиноидов или их аналогов, при среднем диаметре липосомы в формуле в пределах 50-1000 нм.
3. Препарат по п. 2, отличающийся тем, что максимальная конечная концентрация каннабиноидов или их аналогов составляет примерно от 0,01 г/л до 100 г/л.
4. Препарат по п. 2, отличающийся тем, что один или несколько каннабиноидов или их аналогов выбраны из группы в составе каннабинола, каннадибиола, Δ9-тетрагидроканнабинола, Δ8-тетрагидроканнабинола, 11-гидрокси-тетрагидроканнабинола, 11-гидрокси-Δ9-тетрагидро каннабинола, левонантрадола, Δ11-тетрагидроканнабинола, тетрагидроканнабиварина, дронабинола, амандамида и набилона, и комбинации двух или более смесей.
5. Препарат по п. 2, отличающийся тем, что в формулу дополнительно включен стабилизатор, выбранный из группы в составе гуаровой смолы, гиалуроновой кислоты, целлюлозы, ксантановой смолы, поливинилового пирролидона (PVP), альгината, сульфат хондритина, полигаммаглютаминовой кислоты, желатина, хитизина, кукурузного крахмала и муки, в объеме примерно от 0,1% до 2% (процент от объема).
6. Препарат по п. 1, отличающийся тем, что первичный терпен представлен α-пиненом, вторичный терпен выбран из группы в составе мирцена, β-пинена и t-карофиллена, третичный терпен выбран из группы в составе β-пинена, t-карофиллена, α-бизаболола и мирцена, а в суспензию дополнительно входит незначительное количество одного или нескольких терпенов, выбранных из группы в составе α-гумулена, α-бизаболола, гуаена, лимонена, оцимена, терпинолена, 3-карена, миерцена, гуайола, α-терпинеола и
линалоола.
7. Препарат по п. 1, отличающийся тем, что первичный терпен представлен α-бизабололом, а вторичный терпен t-карофилленом, третичный терпен выбран из группы в составе α-пинена и мирцена, а в суспензию дополнительно входит незначительное количество одного или нескольких терпенов, выбранных из группы в составе α-гумулена, α-терпинеола, гуайола и линалоола.
8. Препарат по п. 1, отличающийся тем, что первичный терпен представлен β-пиненом, а вторичный терпен α-пиненом, третичный терпен выбран из группы в составе t-карофиллена и терпинолена, а в суспензию дополнительно входит незначительное количество мирцена.
9. Препарат по п. 1, отличающийся тем, что первичный терпен представлен гуайеном, а вторичный терпен t-карофилленом, третичный терпен выбран из группы в составе мирцена и α-гумулена, а в суспензию дополнительно входит незначительное количество α-пинена, α-бизаболола, β-пинена, лимонена, оцимена и терпинолена.
10. Препарат по п. 1, отличающийся тем, что первичный терпен представлен гуайолом, а вторичный терпен α-бизабололом, третичный терпен выбран из группы в составе t-карофиллена мирцена, а в суспензию дополнительно входит незначительное количество α-пинена, α-терпинеола, α-гумулена и терпинолена.
11. Препарат по п. 1, отличающийся тем, что первичный терпен представлен лимоненом, вторичный терпен выбран из группы в составе мирцена и t-карофиллена, третичный терпен выбран из группы в составе линалоола, мирцена, β-пинена и t-карофиллена, α-бизаболола и мирцена, а в суспензию дополнительно входит незначительное количество одного или нескольких терпенов, выбранных из группы в составе α-гумулена, α-пинена, β-пинена, фенхола, гуайена, линалоола, оцимена и α-терпинеола.
12. Препарат по п. 1, отличающийся тем, что первичный терпен представлен мирценом, вторичный терпен выбран из группы в составе α-пинена, t-карофиллена, терпинолена, оцимена, лимонена и линалоола, третичный терпен выбран из группы в составе β-пинена, t-карофиллена, лимонена, оцимена и мирцена; α-пинена, бизаболола и мирцена, а в суспензию дополнительно входит незначительное количество одного или нескольких терпенов, выбранных из группы в составе α-гумулена, α-бизаболола, гуаена, лимонена, оцимена, 3-карена, β-пинена, α-пинена, миерцена, гуайола, α-терпинеола,
терпинолена и линалоола.
13. Метод приготовления стабильной липосомальной формулы, содержащей один или несколько терпенов, состоит из следующих операций:
(a) растворить один или несколько терпенов в этаноле для получения этанолового раствора терпенов;
(b) добавить фосфолипид в этаноловый раствор терпенов;
(c) произвести впрыск полученного при выполнении операции (b) раствора в дистиллированную воду для получения водно-спиртовой липосомальной формулы терпенов;
(d) извлечь этанол из водно-спиртовой липосомальной формулы терпенов для получения стабильной водной липосомальной формулы с одним или несколькими терпенами, где максимальная конечная концентрация терпенов в липосомальной формуле составляет примерно от 0,01 г/л до 100 г/л.
14. Метод по п. 13, отличающийся тем, что максимальная конечная концентрация терпенов в липосомальной формуле составляет примерно от 10 г/л до 70 г/л.
15. Метод по п. 13, отличающийся тем, что, при выполнении операции (а) дополнительно применяется растворение одного или нескольких каннабиноидов или аналогов каннабиноидов, выбранных из группы в составе каннабинола, каннабидиола, Δ9-тетрагидроканнабинола, Δ8-тетрагидроканнабинола, 11-гидрокси-тетрагидроканнабинола, 11-гидрокси-Δ9-тетрагидроканнабинола, левонантрадола, Δ11-тетрагидроканнабинола, тетрагидроканнабиварина, дронабинола, амандамида, набилона и их сочетаний.
16. Метод по п. 15, отличающийся тем, что средний диаметр липосомов составляет от 50 нм до 1000 нм, а максимальная конечная концентрация каннабиноидов или аналогов каннабиноидов в суспензии - примерно от 0,01 г/л до 100 г/л.
17. Препарат в виде водного раствора терпена и каннабиноида включает в себя первичный терпен, вторичный терпен и третичный терпен, а также один или несколько каннабиноидов или аналогов каннабиноидов, при общем содержании терпена и каннабиноида или терпена и аналога каннабиноида, равном 50 г/л.
RU2016129536A 2013-10-31 2014-10-31 Препараты на основе терпенов и каннабиноидов RU2016129536A (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361898024P 2013-10-31 2013-10-31
US61/898,024 2013-10-31
PCT/IB2014/003156 WO2015068052A2 (en) 2013-10-31 2014-10-31 Terpene and cannabinoid formulations

Publications (1)

Publication Number Publication Date
RU2016129536A true RU2016129536A (ru) 2018-01-31

Family

ID=52811147

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2016129536A RU2016129536A (ru) 2013-10-31 2014-10-31 Препараты на основе терпенов и каннабиноидов

Country Status (10)

Country Link
US (1) US20160279073A1 (ru)
EP (1) EP3062774A2 (ru)
JP (1) JP2016537412A (ru)
KR (1) KR20160094950A (ru)
CN (1) CN105916492A (ru)
AU (1) AU2014347807A1 (ru)
CA (1) CA2929280A1 (ru)
IL (1) IL245368A0 (ru)
RU (1) RU2016129536A (ru)
WO (1) WO2015068052A2 (ru)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11040932B2 (en) 2018-10-10 2021-06-22 Treehouse Biotech, Inc. Synthesis of cannabigerol
US11084770B2 (en) 2016-12-07 2021-08-10 Treehouse Biotech, Inc. Cannabis extracts
US11202771B2 (en) 2018-01-31 2021-12-21 Treehouse Biotech, Inc. Hemp powder

Families Citing this family (124)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10738268B2 (en) * 2016-08-21 2020-08-11 Insectergy, Llc Cannabis nanoemulsion methods
US10595555B2 (en) * 2013-11-04 2020-03-24 Jason Wasserman Methods for creating concentrated plant material solutions
US20160037823A1 (en) * 2014-08-11 2016-02-11 Aari Ruben Medical therapy using cigarettes
MX2017005277A (es) 2014-10-21 2018-01-11 United Cannabis Corp Extractos de cannabis y métodos de preparación y uso de la misma.
US10350165B2 (en) 2014-12-12 2019-07-16 Ojai Energetics Pbc Methods and systems for forming stable droplets
JP2018505912A (ja) * 2014-12-12 2018-03-01 オーハイ エナジェティクス ピービーシー マイクロカプセル化カンナビノイド組成物
CA3050535C (en) 2014-12-15 2021-11-09 Richard Clark Kaufman Methods of treating inflammatory disorders and global inflammation with compositions comprising phospholipid nanoparticle encapsulations of anti-inflammatory nutraceuticals
EP3261629A4 (en) * 2015-02-27 2018-12-05 Ebbu, LLC Compositions comprising combinations of purified cannabinoids, with at least one flavonoid, terpene, or mineral
BR112017018316A2 (pt) 2015-02-27 2018-04-17 Ebbu Llc composições compreendendo combinações de canabinoides purificados, com pelo menos um flavonoide, terpeno ou mineral
US10383816B2 (en) 2015-03-02 2019-08-20 Afgin Pharma, Llc Topical regional neuro-affective therapy with cannabinoid combination products
CN107530318A (zh) 2015-03-02 2018-01-02 阿福金制药有限责任公司 用***素的局部区域神经影响性疗法
AU2015385825A1 (en) * 2015-03-10 2017-10-05 Nanosphere Health Sciences, Llc Lipid nanoparticle compositions and methods as carriers of cannabinoids in standardized precision-metered dosage forms
AU2016231788A1 (en) * 2015-03-19 2017-10-12 One World Cannabis Ltd Preparations of cannabis emulsions and methods thereof
US9962340B2 (en) 2015-06-09 2018-05-08 Life Tech Global, Llc Device and method for the transdermal delivery of cannabidiol
US10272125B2 (en) * 2015-09-14 2019-04-30 Life Tech Global, Llc Transdermal delivery of cannabidiol with other active moieties including cannabinoids
WO2017051398A1 (en) * 2015-09-27 2017-03-30 Buzzelet Development And Technologies Ltd. Methods for the production of different cannabis product compositions
EP3368033A4 (en) * 2015-10-31 2019-06-26 Canabuzz-Med THERAPEUTIC HONEY CANNABINOID COMPOSITION
US11590230B2 (en) * 2015-12-07 2023-02-28 Elka Touitou Compositions of therapeutic substances, methods and uses thereof
US10328216B2 (en) * 2016-01-20 2019-06-25 Flurry Powders, Llc Encapsulation of lipophilic ingredients in dispensible spray dried powders suitable for inhalation
US11833118B2 (en) 2016-01-20 2023-12-05 Flurry Powders, Llc Encapsulation of lipophilic ingredients in dispersible spray dried powders suitable for inhalation
US11166912B2 (en) * 2016-03-03 2021-11-09 Ctt Pharma Inc. Orally administrable composition
CA3017696A1 (en) * 2016-03-16 2017-09-21 Buzzelet Development And Technologies Ltd Terpene-enriched cannabinoid composition
US10542770B2 (en) 2016-03-18 2020-01-28 Aceso Wellness LLC Cannabinoid emulsion product and process for making the same
CN109069459A (zh) * 2016-04-12 2018-12-21 哈比制药私人有限公司 脂质体制剂和治疗方法
EP3445179A4 (en) * 2016-04-19 2020-07-22 Canna-B Cure Ltd ENZYMATICALLY TREATED THERAPEUTIC COMPOSITION ENRICHED IN CANNABIS
US20190142788A1 (en) * 2016-05-04 2019-05-16 Inmed Pharmaceuticals Inc. Use of topical formulations of cannabinoids in the treatment of epidermolysis bullosa and related connective tissue disorders
EP3452026A4 (en) * 2016-05-06 2019-12-25 Harvest Direct Enterprises LLC METHODS OF MANUFACTURE, COMPOSITIONS AND MEDICAL APPLICATIONS OF ORAL-ADDED CANNABIS-BASED PHARMACEUTICAL PRODUCTS
EP3463304A4 (en) * 2016-05-24 2020-01-08 Bol Pharma Ltd. COMPOSITIONS COMPRISING CANNABIDIOL AND HYALURONIC ACID FOR THE TREATMENT OF INFLAMMATORY JOINT DISEASES
US10499584B2 (en) 2016-05-27 2019-12-10 New West Genetics Industrial hemp Cannabis cultivars and seeds with stable cannabinoid profiles
JP6992057B2 (ja) 2016-06-10 2022-01-13 クラリティ コスメティックス インコーポレイテッド 非面皰形成性の毛髪および頭皮ケア製剤ならびにその使用方法
JP7454332B2 (ja) * 2016-06-15 2024-03-22 オーハイ エナジェティクス ピービーシー 酸化ストレスを低減するための方法および組成物
BR112018076283A2 (pt) * 2016-06-15 2019-03-26 Ojai Energetics Pbc métodos e composições para potencializar terapias de célula tronco
IL246790A0 (en) 2016-07-14 2016-09-29 Friedman Doron Self-dissolving compounds of cannabinoids
WO2018017431A1 (en) * 2016-07-16 2018-01-25 Connoisseur Holdings, Llc System and method of forming a terpene solution
WO2018023163A1 (en) 2016-08-03 2018-02-08 Zelda Therapeutics Operations Pty Ltd Cannabis composition
US20180049994A1 (en) 2016-08-16 2018-02-22 Afgin Pharma, Llc Topical regional neuro-affective therapy with caryophyllene
US10568865B2 (en) 2016-08-29 2020-02-25 Canopy Growth Corporation Water soluble compositions comprising purified cannabinoids
WO2018075730A1 (en) * 2016-10-21 2018-04-26 Axim Biotechnologies, Inc. Suppositories comprising cannabinoids
US10857482B1 (en) * 2016-12-07 2020-12-08 Rien Havens Botanical super heated processing equipment
JP7436209B2 (ja) 2016-12-16 2024-02-21 フレーヴァーセンス 活性成分を有する乾燥フレーク
US11974984B2 (en) 2017-02-09 2024-05-07 Caamtech, Inc. Compositions and methods comprising a combination of serotonergic drugs
US20210346346A1 (en) 2017-02-09 2021-11-11 Caamtech, Inc. Compositions comprising a serotonergic tryptamine compound
EP3579832A4 (en) * 2017-02-09 2020-12-30 Caamtech, LLC COMPOSITIONS AND PROCESSES INCLUDING A PSILOCYBIN DERIVATIVE
CN110636834A (zh) * 2017-02-15 2019-12-31 分子浸剂有限公司 制剂
CA3054269A1 (en) * 2017-03-02 2018-09-07 Iiw Entourage Delivery Systems Ltd Aromatized and flavored paper products
EP3600271A4 (en) * 2017-03-30 2020-12-16 Ojai Energetics PBC PROCEDURES AND COMPOSITIONS FOR THE IMPROVEMENT OF HEALTH
WO2018204326A1 (en) * 2017-05-01 2018-11-08 Mj Wooly Corporation Methodology and formulation for creating a powder of an encapsulated cannabis-based component embedded in a polymer matrix
EP3630063A2 (en) 2017-05-22 2020-04-08 GBS Global Biopharma, Inc. Myrcene-containing complex mixtures targeting trpv1
EP3630067A4 (en) * 2017-05-26 2021-08-11 Altum Pharmaceuticals Inc. BIPHASIC CANNABINOID ADMINISTRATION
US10058531B1 (en) * 2017-06-01 2018-08-28 Spartak LLC Dosage delivery film
US10206888B2 (en) 2017-06-06 2019-02-19 Cmg Partners, Inc. Cannabis-based therapeutic product for treatment of chronic pain
WO2019003163A2 (en) * 2017-06-28 2019-01-03 Buzzelet Development And Technologies Ltd. CANNABINOID PRODUCT ENRICHED IN TERPENE GOOD FOR WOMEN'S HEALTH
CA3070156A1 (en) * 2017-07-20 2019-01-24 Yissum Research Development Company Of The Hebrew University Of Jerusam Ltd. Pharmaceutical film compositions for delivery of lipophilic compounds into and/or across the skin
CA3071497A1 (en) * 2017-08-13 2019-02-21 Buzzelet Development And Technologies Ltd Terpene-enriched cannabinoid composition and method of treatment
US11925652B2 (en) * 2017-08-13 2024-03-12 Buzzelet Development And Technologies Ltd Terpene-enriched cannabinoid composition and method of treatment
WO2019057899A1 (en) * 2017-09-22 2019-03-28 Lipid Systems Sp. Z.O.O. AQUEOUS COMPOSITION COMPRISING AT LEAST ONE PHOSHOLIPID AND AT LEAST ONE TERPENE WITH ACIDICITY ACTIVITY AGAINST DEMODEX
US10220061B1 (en) 2017-09-26 2019-03-05 Cynthia Denapoli Method of reducing stress and anxiety in equines
WO2019075006A1 (en) * 2017-10-10 2019-04-18 La'au Pono TREATMENT OF BOTANICAL EXTRACT DRYED BY SPRAYING
WO2019084679A1 (en) * 2017-10-30 2019-05-09 Whistler Technologies Corp. Terpene enrichment methods and systems
EP3704263A4 (en) * 2017-10-30 2021-08-25 Endocanna Health, Inc. GRAPHIC USER INTERFACES FOR DETERMINING PERSONALIZED ENDOCANNABINOID GENOTYPES AND RELATED RECOMMENDATIONS
WO2019100168A1 (en) * 2017-11-27 2019-05-31 Enrico BOUCHARD Method of preparing a cannabis based terpene beverage and beverage thereof
US20200330378A1 (en) * 2018-01-03 2020-10-22 Icdpharma Ltd. Taste-enhanced cannabinoid submicron emulsion syrup compositions
EP3735240A4 (en) * 2018-01-03 2021-08-18 ICDPharma Ltd SOLID SELF-SYSTEMULATING CANNABINOID COMPOSITIONS
BR102018002843A2 (pt) 2018-02-09 2019-08-27 Prati Donaduzzi & Cia Ltda composição farmacêutica e uso da mesma
US11951086B2 (en) 2018-04-03 2024-04-09 Pure Green Pharmaceuticals, Inc. Tablet or composition having n-acyl ethanolamine and cannabinoid
CN112969452A (zh) * 2018-04-09 2021-06-15 艾乐文特科学公司 用于治疗动物疼痛的***提取物
EP3793542A4 (en) * 2018-05-14 2022-03-30 Buzzelet Development And Technologies Ltd TERPENE-ENRICHED CANNABINOID COMPOSITIONS AND THEIR USES IN THE TREATMENT OF INFECTIOUS DISEASES
WO2019226833A1 (en) * 2018-05-22 2019-11-28 Gbs Global Biopharma, Inc. Cannabinoids and/or terpenes for use in trpv1 modulation
US11252985B1 (en) * 2018-05-31 2022-02-22 Cannasphere Biotech, LLC. Dietary supplement compositions including cannabidiol formulations having enhanced bioavailability with sustained time release and enhanced organoleptics, and methods of making same
WO2019237201A1 (en) * 2018-06-12 2019-12-19 Paige Growth Technologies Inc. Devices, systems and methods for multivariable optimization of plant growth and growth of other phototrophic organisms
US10946308B2 (en) * 2018-07-12 2021-03-16 Bright Green Corporation Enzymatic method for extraction and purification of phytocannabinoids
US10946307B2 (en) * 2018-07-12 2021-03-16 Bright Green Corporation Extraction of cannabinoids, curcuminoids and ginsenosides
US11235013B2 (en) 2018-09-04 2022-02-01 Babak Ghalili Cannabinoid, menthol and caffeine dissolvable film compositions, devices and methods
US11185526B2 (en) 2018-09-04 2021-11-30 Babak Ghalili Cannabinoid, menthol and caffeine dissolvable film compositions, devices and methods
US10695301B2 (en) * 2018-09-04 2020-06-30 Babak Ghalili Veterinary cannabinoid and menthol compositions and methods
US11020355B2 (en) * 2018-09-06 2021-06-01 NuVessl, Inc. Method of encapsulating cannabinoids in phospholipid carriers
CA3115985A1 (en) * 2018-10-10 2020-04-16 Tilray, Inc. Methods and formulations for treating chemotherapy-induced nausea and vomiting
EP3873440A4 (en) * 2018-11-01 2022-08-17 Molecular Infusions, LLC POLYMER-BASED ORAL CANNABINOID AND/OR TERPEN FORMULATIONS
KR20210114409A (ko) * 2018-12-11 2021-09-23 디스럽션 랩스 인코퍼레이티드 치료제 전달용 조성물과 이의 이용 및 제조 방법
EP3897684A4 (en) * 2018-12-21 2022-10-12 Botaneco Inc. CANNABINOID FORMULATIONS AND METHODS OF PREPARING THEM
AU2019412825A1 (en) * 2018-12-27 2021-08-12 Buzzelet Development And Technologies Ltd. Herbal preparation-enriched cannabinoid composition and method of treatment
EP3911148A4 (en) * 2019-01-17 2022-10-12 Synthonics, Inc. SOLID MICELLAR COMPOSITIONS OF CANNABINOID ACIDS
US11154502B2 (en) 2019-01-24 2021-10-26 CannaClear Inc. Lecithin vesicles for oral delivery
CA3038349C (en) * 2019-01-31 2021-04-13 Nam Hai LAI Process for producing a nano-cbd liposome system
CA3127476A1 (en) * 2019-02-07 2020-08-13 Cannasoul Analytics Ltd. Cannabinoid containing composition, methods of preparation and use thereof
WO2020163775A1 (en) * 2019-02-08 2020-08-13 Srin Therapeutics, Inc. Cannabinoid compositions and methods of use thereof for immune modulation, immune protection, and treatment of cancer
CA3130763A1 (en) 2019-02-25 2020-09-03 Ginkgo Bioworks, Inc. Biosynthesis of cannabinoids and cannabinoid precursors
AU2020260090C9 (en) * 2019-04-15 2023-08-31 Metagenics LLC Novel hemp and PEA formulation and its use
US10993928B2 (en) * 2019-04-26 2021-05-04 Natural Extraction Systems, LLC Compositions comprising non-crystalline forms of cannabidiol
CN111838746B (zh) * 2019-04-30 2022-04-05 云南汉盟制药有限公司 一种香烟爆珠及其制备方法和香烟
US11298336B2 (en) 2019-05-30 2022-04-12 Soluble Technologies, Inc. Water soluble formulation
CA3141564A1 (en) * 2019-06-03 2020-12-10 Benuvia Manufacturing, Llc Cannabidiol nanocrystal compositions
KR102478632B1 (ko) * 2019-06-18 2022-12-19 바이오메디칼쓰리디프린팅 주식회사 Ｃｂｄ를 포함하는 ３ｄ 객체 및 그의 프린팅 운영 시스템
US20220242050A1 (en) * 2019-06-18 2022-08-04 Bio Medical 3D Printing Co., Ltd. 3d object containing cbd and printing operating system therefor
US11622956B1 (en) * 2019-06-26 2023-04-11 RCR BioPharma Compound and method for treating diseases and disorders
WO2021003091A1 (en) * 2019-07-03 2021-01-07 Vertosa Inc. Infusion of emulsified hydrophobic active ingredients into high polyphenolic beverages
US20210023005A1 (en) * 2019-07-26 2021-01-28 Landsteiner Scientific S.A. De C.V. Cannabinoid-containing compositions in the form of spheres or sphere-like particles, methods for their preparation, and therapeutic applications
WO2021064730A1 (en) * 2019-10-03 2021-04-08 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd Liposomal cannabinoids and uses thereof
GB2588172B (en) * 2019-10-11 2023-05-24 Blackhawk Partners Ltd A pharmaceutical composition comprising cannabinoid
US20220401381A1 (en) * 2019-11-08 2022-12-22 Vella Bioscience, Inc. Peripherally acting cannabidiol (cbd)-containing compounds and uses thereof for enhancing female sexual function or treating female sexual disorders
CA3171272A1 (en) * 2020-03-09 2021-09-16 Gregory S. Baldi Process for making a water soluble, full spectrum hemp oil
WO2021179087A1 (en) * 2020-03-11 2021-09-16 Hexo Operations Inc. Terpene-enhanced compositions and uses thereof
WO2021179088A1 (en) * 2020-03-13 2021-09-16 Hexo Operations Inc. Terpene-enhanced compositions and uses thereof
BR112022023352A2 (pt) * 2020-05-18 2023-05-02 Max Biology Co Ltd Composições, método para fornecer um agente bioativo, preparar uma pluralidade de partículas compósitas, tratar doença do olho seco e tratar uma doença ou afecção e método de uso recreativo
FR3110427B1 (fr) * 2020-05-20 2023-07-14 Laboratoires Eriger Conjugué terpenique de couplage
CN113925896A (zh) * 2020-06-29 2022-01-14 汉义生物科技（北京）有限公司 一种含***提取物的药物组合物、制剂及其应用
US11786475B2 (en) 2020-07-22 2023-10-17 Soluble Technologies Inc. Film-based dosage form
CN111643377B (zh) * 2020-07-23 2023-08-11 中国热带农业科学院南亚热带作物研究所 一种汉麻油纳米微胶囊及其制备方法和应用
EP4188363A1 (en) 2020-07-28 2023-06-07 Wsmef, Llc Micelle preparations of full-spectrum hemp oil for treating type ii diabetes, reducing inflammation during covid-19, and improving sleep quality
WO2022027053A1 (en) * 2020-07-28 2022-02-03 Wsmef, Llc Micelle preparations of full-spectrum hemp oil for treating type ii diabetes, reducing inflammation during covid-19, and improving sleep quality
US20220054446A1 (en) * 2020-08-18 2022-02-24 Yvette Rose Webb Targeted treatment with a topical cream of cannabinoids, terpenes, and essential oils
US11731950B2 (en) * 2020-09-07 2023-08-22 Shuang Xie Mass production and application of Δ 8 THC
AU2021376539A1 (en) * 2020-11-06 2023-06-15 Zelira Therapeutics Operations Pty Ltd Cannabinoid encapsulation technology
WO2022126112A1 (en) * 2020-12-08 2022-06-16 Dt Ip Holdings I, Llc Formulations containing cannabinoids
CA3204862A1 (en) 2020-12-09 2022-06-16 I+Med S. Coop. Composition comprising sea water and cannabinoid loaded submicroparticles for pharmaceutical, nutraceutical and cosmetic applications
CN112472661A (zh) * 2020-12-11 2021-03-12 云南苏旺润生物医药有限公司 一种***二酚按摩油组合物及其制备方法和应用
CA3102947A1 (en) * 2020-12-18 2022-06-18 Skymount Medical Us Inc. Nutraceuticals useful in the treatment of coronavirus diseases
US20240049760A1 (en) * 2020-12-24 2024-02-15 Petro Pawlo Czupiel Safe-to-ingest microemulsions and nanoemulsions containing lipophilic components
WO2022140849A1 (en) * 2021-01-04 2022-07-07 Hexo Operations Inc. Cannabinoid compositions with taste-barrier properties
WO2022165165A1 (en) * 2021-01-29 2022-08-04 The Johns Hopkins University Limonene effects on tetrahydrocannabinol (thc)-induced anxiety
US12011470B2 (en) 2021-07-28 2024-06-18 Clint Sorensen Micelle preparations of full-spectrum hemp oil
WO2023060323A1 (en) * 2021-10-15 2023-04-20 Bod Science Limited Terpene-containing formulations and use thereof
WO2023212170A1 (en) * 2022-04-29 2023-11-02 Abstrax Tech Inc. Endogenous stabilization of cannabinoids
WO2024057304A1 (en) * 2022-09-12 2024-03-21 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Compositions for dermal/transdermal delivery and cosmetic use

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0927025A4 (en) * 1996-09-18 2001-07-25 Dragoco Inc DRY POWDER COMPOSITION WITH ACTIVE INGREDIENT ENCLOSED IN LIPOSOMES
US20030180349A1 (en) * 2001-12-07 2003-09-25 Franklin Lanny U. Respiratory infection prevention and treatment with terpene-containing compositions
GB0202385D0 (en) * 2002-02-01 2002-03-20 Gw Pharma Ltd Compositions for the treatment of nausea,vomiting,emesis,motion sicknes or like conditions
CA2659775A1 (en) * 2006-08-04 2008-02-14 Insys Therapeutics Inc. Aqueous dronabinol formulations
EP2201942A1 (de) * 2008-12-23 2010-06-30 Intendis GmbH Zusammensetzung mit Hanföl für die Behandlung topischer Erkrankungen
GB2478595B (en) * 2010-03-12 2018-04-04 Gw Pharma Ltd Phytocannabinoids in the treatment of glioma
GB2479153B (en) * 2010-03-30 2014-03-19 Gw Pharma Ltd The phytocannabinoid cannabidivarin (CBDV) for use in the treatment of epilepsy
WO2013009928A1 (en) * 2011-07-11 2013-01-17 Organic Medical Research Cannabinoid formulations

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11084770B2 (en) 2016-12-07 2021-08-10 Treehouse Biotech, Inc. Cannabis extracts
US11202771B2 (en) 2018-01-31 2021-12-21 Treehouse Biotech, Inc. Hemp powder
US11040932B2 (en) 2018-10-10 2021-06-22 Treehouse Biotech, Inc. Synthesis of cannabigerol

Also Published As

Publication number Publication date
JP2016537412A (ja) 2016-12-01
CN105916492A (zh) 2016-08-31
IL245368A0 (en) 2016-06-30
WO2015068052A2 (en) 2015-05-14
EP3062774A2 (en) 2016-09-07
KR20160094950A (ko) 2016-08-10
CA2929280A1 (en) 2015-05-14
WO2015068052A3 (en) 2015-09-03
US20160279073A1 (en) 2016-09-29
AU2014347807A1 (en) 2016-05-26

Similar Documents

Publication Publication Date Title
RU2016129536A (ru) Препараты на основе терпенов и каннабиноидов
JP2016537412A5 (ru)
PE20190318A1 (es) Composicion administrable oralmente
Bhosale et al. Synergistic effects of zeaxanthin and its binding protein in the prevention of lipid membrane oxidation
US10406189B2 (en) Methods and compositions for treating and preventing signs or symptoms of eye disease
de Freitas et al. Influence of aqueous crude extracts of medicinal plants on the osmotic stability of human erythrocytes
CN105832569A (zh) 一种水分散型透明虾青素乳液及其制备方法
Carvalho et al. Anti-Leishmania activity of essential oil of Myracrodruon urundeuva (Engl.) Fr. All.: Composition, cytotoxity and possible mechanisms of action
MX2014013884A (es) Sistema de vehiculo oftalmologico para farmacos, kit oftalmologico y tambien uso de una composicion oftalmologica.
EP2635266A1 (de) Zusammensetzung und arzneimittel enthaltend omega-3-fettsäuren sowie einen modulator
BR112016029544A2 (pt) partículas de sílica porosa, método de fabricação e produto cosmético contendo as mesmas
MX2012014443A (es) Composiciones oftalmicas para la administracion de ingredientes activos liposolubles.
JP2019523283A (ja) ***組成物
WO2009063962A1 (ja) 薬物含有脂肪乳剤およびその製造方法
BR112021024836A2 (pt) Artigo para uso em um sistema de provisão de aerossol não combustível, sistema e método de fabricação de um artigo para uso em um sistema de provisão de aerossol não combustível
Khor et al. Potential antioxidant and cytotoxic properties of secondary metabolite extracts from Carica papaya fruits and seeds
EP3220934B1 (en) Biologically-active tomato composition having reduced amount of lycopene
Hagiwara et al. ETS-GS, a new antioxidant, ameliorates renal ischemia-reperfusion injury in a rodent model
CL2012000515A1 (es) Sustancia colorante dispersable en agua que comprende carbo vegetabilis y por lo menos 1% de un derivado de octenil succinato de almidón como agente dispersante; método de preparación de la sustancia colorante; su uso; y producto comestible y farmacéutico que lo contienen.
CN103767070B (zh) 角鲨烯与虾青素组合物液态前体脂质体的制备方法及其降基减害应用
CN103859588A (zh) 角鲨烯与虾青素组合物多囊脂质体的制备及其降基减害
CN104940972B (zh) 一种精油组合物及其微胶囊化方法及用其制备的安神助眠香薰纸及其应用
Reyad-ul-Ferdous et al. Phytochemical screening, in-vitro membrane stabilizing and thrombo-lytic activities of Lophopetalum javanicum
CN110326814B (zh) 龙脑精油爆珠及其应用
Gelatti et al. Effect of Cymbopogon citratus on oxidative stress markers in erythrocytes from post menopausal women: A pilot study

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20190404